Exhibit (a) to Form 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT
                       Pursuant to Section 13 and 15(d) of
                       the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):                 June 15, 2001


                         Human Pheromone Sciences, Inc.
                         ------------------------------
             (Exact name of Registrant as specified in its charter)


     CALIFORNIA                       0-23544                   94-3107202
     ----------                       -------                   ----------
(State or other jurisdiction       (Commission                (IRS Employer
      of incorporation)            File Number)            Identification No.)


84 West Santa Clara Street, Suite 720, San Jose, California         95113
-----------------------------------------------------------         -----
     (Address of principal executive offices)                     (Zip code)


Registrant's telephone number, including area code:              (408) 938-3030
                                                                 --------------


               46750 Fremont Boulevard, Fremont, California 94538
            --------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

<PAGE>
Exhibit (a) to Form 10-QSB

                    INFORMATION TO BE INCLUDED IN THE REPORT


ITEM 4.      CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANTS

             The Audit  Committee of the Company  authorized the  termination of
             BDO Seidman LLP as auditors of the Company effective June 15, 2001.
             The  reports  of  BDO  Seidman  LLP  on  the  Company's   financial
             statements for the past two fiscal years did not contain an adverse
             opinion  or a  disclaimer  of  opinion  and were not  qualified  or
             modified as to uncertainty, audit scope, or accounting principles.

             In connection with the audits of the Company's financial statements
             for each of the two fiscal years ended  December  31, 2000,  and in
             the subsequent  interim period through the date hereof,  there were
             no disagreements  with BDO Seidman LLP on any matters of accounting
             principles  or  practices,   financial  statement  disclosure,   or
             auditing  scope  and  procedures  which,  if  not  resolved  to the
             satisfaction  of BDO  Seidman LLP would have caused BDO Seidman LLP
             to make  reference to the matter in their  report.  The Company has
             requested  BDO Seidman LLP to furnish it a letter  addressed to the
             Commission  stating whether it agrees with the above statements.  A
             copy of that letter,  dated June 20, 2001,  is filed as Exhibit 7.1
             to this Form 8-K.


ITEM 7       FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

             Exhibit 7.1 - Letter from BDO Seidman LLP  pursuant to Item 304 (a)
             (3) of Regulation S-K.



<PAGE>
Exhibit (a) to Form 10-QSB


                                   SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                      HUMAN PHEROMONE SCIENCES, INC.



                                      By: /s/ William P. Horgan
                                      ------------------------------------------
                                      William P. Horgan, Chief Executive Officer